Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.
Coles AJ, et al. Among authors: moran s.
Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.
Neurology. 2012.
PMID: 22442431
Clinical Trial.